Nurix Therapeutics Inc (NRIX) Stock Price, Quote & News

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BT...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 660 5320

Fax: 415 525 4200

Website: www.nurixtx.com

Address:

1700 Owens Street, Suite 205, San Francisco, United States

JarvisFlow Jul. 15 at 1:00 PM

Morgan Stanley has updated their rating for Nurix Therapeutics ( $NRIX ) to Equal-Weight with a price target of 16.

0 · Reply

Wilburbeast69 Jul. 14 at 9:53 PM

$NRIX

0 · Reply

JarvisFlow Jul. 14 at 2:17 PM

HC Wainwright & Co. updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 36 → 34.

0 · Reply

d_risk Jul. 11 at 2:13 PM

$NRIX - Nurix Therapeutics Inc. Common stock - 10Q - Updated Risk Factors NRIX’s 2025 10-Q risk update spotlights early-stage clinical and manufacturing challenges for lead drugs including zelebrudomide, high development costs, uncertain profitability, expanded IP risks, regulatory complexities (FDA, UK, post-approval), potential dilution from capital raises, and evolving pricing and legal landscapes; several prior risk factors on collaborations, competition, and cybersecurity were removed or streamlined. #Biotechnology #FinancialRisk #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/NRIX/10-Q/2025-07-09

0 · Reply

Anakin06 Jul. 11 at 9:37 AM

$NRIX after this big lost yesterday we have I hope the bottom. We can just go up now no ?

2 · Reply

AustinBrussels Jul. 11 at 6:11 AM

$NRIX down 3,16% overnight, that's crazy. From 22 to 12 in a day

1 · Reply

JarvisFlow Jul. 10 at 10:30 PM

UBS has adjusted their stance on Nurix Therapeutics ( $NRIX ), setting the rating to Buy with a target price of 30 → 26.

0 · Reply

Ravbcentinal Jul. 10 at 8:17 PM

$NRIX after hours!

1 · Reply

PsychoPass Jul. 10 at 8:04 PM

$NRIX started little position at 12,68$

0 · Reply

BuyThemCheapStackemDeep Jul. 10 at 6:46 PM

$NRIX PaYtience pays!. ⏰

1 · Reply

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

Jul 9, 2025, 4:01 PM EDT - 7 days ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 7, 2025, 7:00 AM EDT - 9 days ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jun 13, 2025, 4:01 PM EDT - 4 weeks ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

Jun 12, 2025, 7:00 AM EDT - 4 weeks ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 6, 2025, 7:00 AM EDT - 5 weeks ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 2, 2025, 7:00 AM EDT - 6 weeks ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

May 28, 2025, 7:00 AM EDT - 7 weeks ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 2 months ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:30 AM EDT - 2 months ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Apr 28, 2025, 4:00 PM EDT - 2 months ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 25, 2025, 1:00 PM EDT - 2 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 17, 2025, 5:07 PM EDT - 3 months ago

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Apr 17, 2025, 7:00 AM EDT - 3 months ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 8, 2025, 4:00 PM EDT - 3 months ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 2, 2025, 7:00 AM EDT - 3 months ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 25, 2025, 4:30 PM EDT - 4 months ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 4 months ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 13, 2025, 4:00 PM EDT - 4 months ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Mar 4, 2025, 7:00 AM EST - 4 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Feb 4, 2025, 7:00 AM EST - 5 months ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 4:00 PM EST - 6 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 22, 2025, 7:00 AM EST - 6 months ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 9, 2025, 8:44 AM EST - 6 months ago

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Jan 6, 2025, 7:00 AM EST - 6 months ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia$

Dec 19, 2024, 7:00 AM EST - 7 months ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 9, 2024, 6:00 PM EST - 7 months ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Dec 2, 2024, 7:00 AM EST - 8 months ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nov 25, 2024, 7:00 AM EST - 8 months ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

$Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia$

Nov 20, 2024, 4:00 PM EST - 8 months ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nov 17, 2024, 10:30 AM EST - 8 months ago

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Oct 21, 2024, 4:00 PM EDT - 9 months ago

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

$Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia$

Oct 19, 2024, 8:00 AM EDT - 9 months ago

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Oct 16, 2024, 4:35 PM EDT - 9 months ago

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

Oct 11, 2024, 4:00 PM EDT - 9 months ago

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Oct 9, 2024, 7:00 AM EDT - 10 months ago

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

Oct 8, 2024, 10:58 AM EDT - 10 months ago

Nurix: An Attractive Early-Stage Biotech Play

Sep 30, 2024, 7:00 AM EDT - 10 months ago

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

Sep 6, 2024, 7:00 AM EDT - 11 months ago

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

Sep 4, 2024, 11:59 AM EDT - 11 months ago

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Jul 11, 2024, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Jun 19, 2024, 9:27 AM EDT - 1 year ago

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

$Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)$

Jun 16, 2024, 5:30 AM EDT - 1 year ago

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

May 28, 2024, 7:00 AM EDT - 1 year ago

Nurix Therapeutics Appoints Paula G. O'Connor, M.D.

May 20, 2024, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Announces Board Chair Transition

May 14, 2024, 10:00 AM EDT - 1 year ago

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

May 7, 2024, 7:00 AM EDT - 1 year ago

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

Apr 16, 2024, 6:21 PM EDT - 1 year ago

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 11, 2024, 11:38 PM EDT - 1 year ago

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Apr 11, 2024, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Announces Proposed Public Offering

JarvisFlow Jul. 15 at 1:00 PM

Morgan Stanley has updated their rating for Nurix Therapeutics ( $NRIX ) to Equal-Weight with a price target of 16.

0 · Reply

Wilburbeast69 Jul. 14 at 9:53 PM

$NRIX

0 · Reply

JarvisFlow Jul. 14 at 2:17 PM

HC Wainwright & Co. updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 36 → 34.

0 · Reply

d_risk Jul. 11 at 2:13 PM

0 · Reply

Anakin06 Jul. 11 at 9:37 AM

$NRIX after this big lost yesterday we have I hope the bottom. We can just go up now no ?

2 · Reply

AustinBrussels Jul. 11 at 6:11 AM

$NRIX down 3,16% overnight, that's crazy. From 22 to 12 in a day

1 · Reply

JarvisFlow Jul. 10 at 10:30 PM

UBS has adjusted their stance on Nurix Therapeutics ( $NRIX ), setting the rating to Buy with a target price of 30 → 26.

0 · Reply

Ravbcentinal Jul. 10 at 8:17 PM

$NRIX after hours!

1 · Reply

PsychoPass Jul. 10 at 8:04 PM

$NRIX started little position at 12,68$

0 · Reply

BuyThemCheapStackemDeep Jul. 10 at 6:46 PM

$NRIX PaYtience pays!. ⏰

1 · Reply

BuyThemCheapStackemDeep Jul. 10 at 3:39 PM

$NRIX You won’t shake me out. Know what you hold!

1 · Reply

kshonstocks Jul. 10 at 3:15 PM

$NRIX Short Interest Ratio (Days To Cover) 15.3 https://shortsqueeze.com/?symbol=NRIX

0 · Reply

kshonstocks Jul. 10 at 3:04 PM

$NRIX buyers from the lows, keep an eye on it

0 · Reply

stockaura Jul. 10 at 2:45 PM

$NRIX burning 80m per quarter and multiple downgrades. Reason for reversal. Good pipeline tho

1 · Reply

The_Illuminati Jul. 10 at 2:40 PM

$NRIX Daylight robbery. The US stock market! 🤮

0 · Reply

BuyThemCheapStackemDeep Jul. 10 at 2:10 PM

$NRIX 🎁 🎁 🎁 🎁 Christmas in July

1 · Reply

Anakin06 Jul. 10 at 2:05 PM

$NRIX well never buy a good news in premarket! I didn't know

2 · Reply

BuyThemCheapStackemDeep Jul. 10 at 2:04 PM

$NRIX 🥱 Shopping day, I have PaYtience

0 · Reply

MaxDanger Jul. 10 at 1:39 PM

$NRIX this stock has significant short interest. 900k shares traded premarket. Those weak hands are nervous and selling to save their losses, while allowing the shorts to mediate their losses and cover before it inevitably goes back to 20+.

0 · Reply

Dojacay Jul. 10 at 1:38 PM

$NRIX They want your cheap shares, we got 22$ on premarket. Dont be foolish

1 · Reply

The_Illuminati Jul. 10 at 1:35 PM

$NRIX Crazy movement on this stock today. Like WTF! Bullish though.

0 · Reply

Anakin06 Jul. 10 at 1:33 PM

$NRIX well I don't get it it was a bad news ?

2 · Reply

Market Cap	970.14M
Revenue (ttm)	54.55M
Net Income (ttm)	-193.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-354.85%
Debt to Equity Ratio	0.00

Volume	774,400
Avg Vol	886,392
Day's Range	N/A - N/A
Shares Out	76.45M
Stochastic %K	22%
Beta	2.15
Analysts	Strong Sell
Price Target	$29.47